Market Place
Sourcing Support
BMS` Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.
22 Mar 2022 //
FDA
Indapta Therapeutics Announces New Preclinical Data for Proprietary G-NK Cells
10 Aug 2021 //
BUSINESSWIRE
Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US
31 Oct 2019 //
FDA
Empliciti combo bags EU approval for multiple myeloma
29 Aug 2019 //
PHARMA TIMES
EC OKs expanded label for Bristol-Myers` Empliciti
27 Aug 2019 //
SEEKINGALPHA
J&J eyes Darzalex convenience, safety boost with subcutaneous win
05 Jun 2019 //
FIERCE PHARMA
BMY`s to Present New Data on 20 Types Cancer from Across its Oncology Portfolio
17 May 2019 //
PRESS RELEASE
US approves new use for BMS’ Empliciti
08 Nov 2018 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.